News, Articles & Media

Posts Tagged ‘Jim Watson’

Caldera close to global breakthrough on new prostate cancer test, seeks new investors

Jonathan Underhill reports in NBR on Caldera’s work on a gene-sequencing replacement for the world’s most widely used prostate cancer test.

Jim caldera2211030www

Caldera Health founder Jim Watson

Monday 18 May, 2015 – Caldera Health, a New Zealand biotech company working on a gene-sequencing replacement for the world’s most widely used prostate cancer test, is seeking new investors to complete a $2 million capital raising to finish clinical studies and put the research in front of potential commercial partners.

Auckland-based Caldera has attracted $5.93 million of investment since being incorporated in 2009, made up of $5.4 million from investors including New Image Group founder Graeme Clegg, Stephen Tindall’s K One W One, the government’s NZ Venture Investment Fund, and about $568,000 from Callaghan Innovation and its predecessors. It has raised about $1.1 million of the $2 million sought in its latest offer of 2.5 million shares at 80c apiece. Each share comes with a ‘stapled’ option to buy another share at that price by 2017. Investors need to put in a minimum of $750,000.

Read the full NBR article here

May 2015 Newsletter to Shareholders

Read the May 2015 Newsletter for news on the following:

  • The appointment of a new Director of Research and Development
  • Our recent project review,
  • The R&D growth grant we received from Callaghan Innovation
  • Migrating our accounting system to the cloud
  • Two further staff appointments.

This newsletter also contains a third article on prostate cancer from Dr Jim Watson.

November 2014 Newsletter to Shareholders

Read the November 2014 newsletter for updates on new premises, Clinical Study 2, new investment, accounting, new staff, the Annual Meeting.

This newsletter also contains the second of Dr Jim Watson’s opinion pieces on prostate cancer.

August 2014 Newsletter to Shareholders

Read the August 2014 newsletter for updates on new investment, R&D grants from Callaghan Innovation, Clinical Study 2, collaboration with Malaghan Institute, accounting, new premises, new staff and Chiasma – an Auckland University student-led organisation fostering connections between science and business.

This newsletter also contains the first of Dr Jim Watson’s opinion pieces about prostate cancer.